Real-World data reveals patterns in advanced breast cancer treatment
NCT ID NCT04498481
First seen Feb 28, 2026 · Last updated May 15, 2026 · Updated 10 times
Summary
This study reviewed medical records of women with advanced or metastatic HR+/HER2- breast cancer who were treated with palbociclib plus an aromatase inhibitor or fulvestrant in community clinics. The goal was to understand real-world treatment patterns, how long patients stayed on therapy, and their outcomes like survival and tumor response. It did not test a new treatment but gathered information to improve future care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Pfizer United States
New York, New York, 10017, United States
Conditions
Explore the condition pages connected to this study.